Related Experiment Video
Updated: Jan 19, 2026

Author Spotlight: Understanding Chronic Lung Diseases Using 3D Printed Phototunable Hydrogels
Published on: June 30, 2023
Fibroblast Activation Protein is a GH Target: A Prospective Study of Patients with Acromegaly Before and After
Mai C Arlien-Søborg1,2, Camilla Grøndahl1, Amanda Bæk1
1Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Denmark.
Background:
Fibroblast growth factor 21 (FGF21) is a circulating hormone with pleiotropic metabolic effects, which is inactivated by fibroblast activation protein (FAP). Data regarding interaction between FGF21, FAP, and growth hormone (GH) are limited, but it is noteworthy that collagens are also FAP substrates, since GH potently stimulates collagen turnover.
Aim:
To measure circulating FGF21 components, including FAP, in patients with acromegaly before and after disease control.
Methods:
Eighteen patients with active acromegaly were studied at the time of diagnosis and ≥ 6 months after disease control by either surgery or medical treatment. Serum levels of total and active FGF21, β-klotho, FAP, and collagen turnover markers were measured by immunoassays. Expression of putative FGF21-dependent genes were measured in adipose tissue by reverse transcriptase-polymerase chain reaction, body composition assessed by dual-energy x-ray absorptiometry scan, and insulin sensitivity estimated with homeostatic model assessment of insulin resistance (HOMA-IR).
Results:
Total FGF21, active FGF21 and β-klotho remained unchanged. Insulin sensitivity and body fat mass increased after disease control but neither correlated with active FGF21. Expression of FGF21-dependent genes did not change after treatment. FAP levels (µg/L) were markedly reduced after treatment [105.6 ± 29.4 vs 62.2 ± 32.4, P < 0.000]. Collagen turnover markers also declined significantly after treatment and ΔFAP correlated positively with ΔProcollagen Type I (P < 0.000) and Type III (P < 0.000).
Conclusion:
1) Circulating FGF21 and β-klotho do not change in response to acromegaly treatment, 2) FAP concentrations in serum decrease after disease control and correlate positively with collagen turnover markers, and 3) FAP is a hitherto unrecognized GH target linked to collagen turnover.
Clinical Trials Registration:
NCT00647179.
Insights
Fibroblast growth factor 21 (FGF21) and β-klotho levels did not change in acromegaly patients after treatment. However, fibroblast activation protein (FAP) levels decreased, correlating with reduced collagen turnover, suggesting FAP is a growth hormone (GH) target.
Area of Science:
- Endocrinology
- Metabolic Research
Background:
- Fibroblast growth factor 21 (FGF21) is a metabolic hormone inactivated by fibroblast activation protein (FAP).
- Limited data exist on FGF21, FAP, and growth hormone (GH) interactions, despite GH stimulating collagen turnover, a known FAP substrate.
Purpose of the Study:
- To quantify circulating FGF21, FAP, and related markers in acromegaly patients before and after treatment.
- To investigate the relationship between FGF21, FAP, GH, and collagen turnover in acromegaly.
Main Methods:
- Studied 18 active acromegaly patients at diagnosis and after disease control (surgery/medical).
- Measured serum FGF21 (total/active), β-klotho, FAP, and collagen turnover markers via immunoassays.
- Assessed gene expression, body composition, and insulin resistance (HOMA-IR).
Main Results:
- Total FGF21, active FGF21, and β-klotho remained unchanged post-treatment.
- Insulin sensitivity and body fat mass improved, but did not correlate with active FGF21.
- Serum FAP levels significantly decreased post-treatment (105.6 ± 29.4 vs 62.2 ± 32.4 µg/L).
- Collagen turnover markers also declined significantly, with FAP reduction correlating positively with Procollagen Type I and III.
Conclusions:
- Circulating FGF21 and β-klotho are unaffected by acromegaly treatment.
- Serum FAP concentrations decrease after disease control and correlate with collagen turnover.
- FAP emerges as a novel GH target associated with collagen turnover in acromegaly.
Related Concept Videos
TGF - β Signaling Pathway
Introduction to Fibroblasts
Abnormal Proliferation
GPCRs Regulate Adenylyl Cylase Activity
Mitogens and the Cell Cycle

![An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F66708.jpg&w=3840&q=50)